Efficacy and safety of topical JAK inhibitors in the treatment of atopic dermatitis in paediatrics and adults: A systematic review

Article Dermatology

The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial

Margitta Worm et al.

Summary: This trial demonstrated the efficacy and tolerability of delgocitinib cream in the treatment of chronic hand eczema.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Review Allergy

Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors

Chisa Nakashima et al.

Summary: Atopic dermatitis is a chronic, eczematous skin condition characterized by severe itchiness. Th2 cell-mediated immunity, skin barrier dysfunction, and pruritus contribute to the development of atopic dermatitis. The JAK/STAT pathway is involved in various inflammatory diseases, including atopic dermatitis. JAK inhibitors show promise as potential treatments for severe atopic dermatitis.

ALLERGOLOGY INTERNATIONAL (2022)

Add to Collection

Article Dermatology

A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis

Robert Bissonnette et al.

Summary: In this study, the safety, tolerability, and bioavailability of 1.5% ruxolitinib cream were evaluated under maximum-use conditions in patients with atopic dermatitis. The results showed that the cream was well-tolerated with only a few treatment-related adverse events. The plasma concentration of ruxolitinib remained below the level expected to affect bone marrow production of blood cells, and the cream demonstrated high efficacy in patients with larger affected body surface areas.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2022)

Add to Collection

Review Dermatology

Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis

Chenyang Li et al.

Summary: This study assessed the efficacy and safety of Janus kinase (JAK) inhibitors for atopic dermatitis (AD) treatment through randomized clinical trials. The results showed that JAK inhibitors significantly improved IGA response and EASI score, with topical inhibitors proving more efficacious than oral ones. The study concluded that JAK inhibitors are effective and safe for AD treatment, but suggested the need for further trials with longer duration and head-to-head comparisons of different JAK inhibitors.

DERMATOLOGY (2022)

Add to Collection

Review Dermatology

Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis

Hannah Wood et al.

Summary: JAK inhibitors are a new class of drugs that target proteins in the JAK-STAT pathway to reduce inflammatory responses in atopic dermatitis. Clinical trials show that oral JAK inhibitors can cause adverse events such as nausea, upper respiratory tract infection, headache, and herpes zoster, while topical JAK inhibitors do not have systemic effects.

INTERNATIONAL JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Review Immunology

A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders

Yasamin Kalantari et al.

Summary: Janus kinases (JAKs) are important intracellular proteins that regulate cell signaling. Inhibition of JAK/STAT pathways shows potential for treating autoimmune and autoinflammatory diseases, especially in dermatology. This study evaluated the efficacy of JAK inhibitors in treating immunobullous diseases and found promising results.

INTERNATIONAL IMMUNOPHARMACOLOGY (2022)

Add to Collection

Letter Allergy

Refractory nummular eczema in child successfully treated with NB-UVB and topical delgocitinib

Ichiro Kurokawa et al.

JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY (2022)

Add to Collection

Article Allergy

Clinical effect of delgocitinib 0.5% ointment on atopic dermatitis eczema intensity and skin barrier function

Masatoshi Abe et al.

Summary: Treatment with delgocitinib 0.5% ointment was well tolerated and showed improvements in both eczema and skin hydration in adult patients with atopic dermatitis.

JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY (2022)

Add to Collection

Review Dermatology

Janus kinase inhibitors for atopic dermatitis: a promising treatment modality

A. M. Cartron et al.

Summary: Atopic dermatitis is a chronic inflammatory skin disease that can significantly impact sleep quality and quality of life. Recent studies suggest that inhibition of the JAK signaling pathway may offer a promising therapeutic approach to reduce inflammation in AD.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2021)

Add to Collection

Letter Dermatology

A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis

[Anonymous]

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study

Hidemi Nakagawa et al.

Summary: The study evaluated the efficacy and safety of Delgocitinib ointment in Japanese pediatric patients with AD. Results showed significant improvement in AD in the short term and maintenance of improvement with long-term use.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Letter Dermatology

A case of facial redness in atopic dermatitis occurring during dupilumab treatment successfully treated with topical delgocitinib ointment

Tomomitsu Miyagaki et al.

DERMATOLOGIC THERAPY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials

Xiaoliang Yang et al.

Summary: AD is an inflammatory skin disease influenced by genetics, immune response, and environment. Therapies like dupilumab, crisaborole, and delgocitinib provide hope for effective treatment, and offer insight into the pathophysiology of AD.

PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Dermatology

Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

Kim Papp et al.

Summary: The study evaluated the efficacy and safety of RUX cream in patients with AD, showing significant effects on reducing itch and improving skin inflammation, with superior efficacy compared to vehicle cream and good tolerability.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Review Health Care Sciences & Services

Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials

Hou-Ren Tsai et al.

Summary: JAK inhibitors show promising efficacy in treating AD, but with a higher risk of treatment-emergent adverse events. Long-term follow-up is needed to assess the safety profile.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection

Letter Dermatology

Remission of Severe Eyelid Dermatitis With a Topical Janus Kinase Inhibitor

Danielle Peterson et al.

DERMATITIS (2021)

Add to Collection

Review Dermatology

The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis

Lu Zhang et al.

Summary: The study compared the efficacy of JAK inhibitors for AD treatment and found promising results, showing that JAK inhibitors had good treatment efficacy for AD patients, with upadacitinib and delgocitinib performing well among all included formulations.

DERMATOLOGIC THERAPY (2021)

Add to Collection

Article Allergy

Innate Immune Regulation of Dermatitis

Damien Abreu et al.

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2021)

Add to Collection

Review Allergy

JAK inhibitors in the treatment of atopic dermatitis

Raj Chovatiya et al.

Summary: Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options. Recent studies have shown that both topical and systemic Janus kinase (JAK) inhibitors hold promise in treating AD, with further research needed to fully understand their efficacy and safety.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Dermatology

Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis

Lu Zhang et al.

Summary: This study compared the efficacy and safety of topical Janus kinase (JAK) and phosphodiesterase-4 (PDE4) inhibitors for atopic dermatitis (AD) treatment. The results showed that these inhibitors had higher IGA response compared to placebo and demonstrated a comparable safety profile.

JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

26900 A phase 2b trial evaluating the efficacy of delgocitinib cream for the treatment of chronic hand eczema (CHE) using and validating the Hand Eczema Severity Index (HECSI)

Per Soerensen et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

27620 Effects of ruxolitinib cream in patients with atopic dermatitis with baseline body surface area ≥10% and Eczema Area and Severity Index score ≥16: Pooled results from two phase 3 studies

Eric L. Simpson et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

28200 Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: Pooled results from two phase 3 studies

Lawrence F. Eichenfield et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

26884 Ruxolitinib cream rapidly decreases pruritus in atopic dermatitis: Pooled results from two phase 3 studies

Andrew Blauvelt et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

26887 Effect of ruxolitinib cream on sleep disturbance and sleep impairment: Pooled analysis from two randomized phase 3 studies

Eric L. Simpson et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Microbiology

Bacterially Delivered miRNA-Mediated Toll-like Receptor 8 Gene Silencing for Combined Therapy in a Murine Model of Atopic Dermatitis: Therapeutic Effect of miRTLR8 in AD

Wonsuck Yoon et al.

Summary: This study investigated the therapeutic effects of TLR8 gene silencing by utilizing bacterial delivery of miRNA on atopic dermatitis. The down-regulation of TLR8 resulted in decreased cytokine levels, suppressed IgE and interleukin-4 production, and induced IFN-gamma, leading to improved scratching behaviors and skin inflammation. The use of Salmonella vectors for TLR gene modulation via miRNA showed a double-protective effect in the treatment of AD.

MICROORGANISMS (2021)

Add to Collection

Review Dermatology